Beam Therapeutics announced positive Phase 1/2 trial results for BEAM-302, a base editing therapy for alpha-1 antitrypsin deficiency (AATD). The 60 mg dose achieved mean steady-state AAT levels of 16.1 µM with durable results, 94% corrected M-AAT production, and 84% reduction in mutant Z-AAT. The therapy demonstrated a well-tolerated safety profile with no serious adverse events. Beam selected 60 mg as the optimal biological dose and plans to initiate a pivotal cohort in the second half of 2026 to support an accelerated approval pathway.
Beam Therapeutics Inc. Common Stock (BEAM)
Common Stock · Currency in USD · XNAS
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Company Info
SIC2836
Composite FIGIBBG00KXC8646
CIK0001745999
IPOFeb 6, 2020
Sectorbiological products, (no diagnostic substances)
Highlights
Market Cap$2.51B
EPS-$4.40
P/E Ratio-5.57
Revenue$36.33M
Gross Profit$38.79M
Net Income-$450.91M
Employees511
WSO101,856,245
Phone857-327-8775
Websitehttps://www.beamtx.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Beam Therapeutics Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Beam Therapeutics Inc. Common Stock (BEAM) has returned -11.23% so far this year and 69.95% over the past 12 months. Looking at the last ten years, BEAM has achieved an annualized return of 0.27%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
BEAM
1M-7.68%
6M-5.23%
YTD-11.23%
1Y69.95%
5Y-18.90%
10Y0.27%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Beam Therapeutics Inc. Common Stock (BEAM) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.58% | 3.45% | -12.65% | 2.66% | ||||||||
| 2025 | 4.43% | 5.28% | -26.41% | 2.47% | -20.61% | 6.31% | 16.97% | -14.21% | 49.91% | 3.52% | 2.68% | 11.86% |
| 2024 | -9.46% | 60.79% | -17.42% | -35.50% | 11.99% | -2.98% | 34.93% | -14.27% | -6.99% | -10.20% | 22.74% | -9.26% |
| 2023 | 8.79% | -9.35% | -23.45% | 0.79% | 4.04% | -0.03% | -3.26% | -23.78% | 2.87% | -11.92% | 31.28% | -2.51% |
| 2022 | -13.22% | 11.28% | -26.33% | -35.36% | -5.89% | 9.35% | 61.49% | -4.86% | -11.14% | -10.32% | 1.54% | -15.66% |
| 2021 | 18.12% | -10.61% | -13.50% | 0.35% | -5.69% | 63.44% | -28.94% | 19.45% | -21.16% | 2.02% | -11.55% | 0.38% |
| 2020 | -6.29% | -22.08% | -7.86% | 61.61% | 9.37% | -31.39% | 21.30% | -1.52% | 40.33% | 45.14% | 59.24% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Beam Therapeutics Inc. Common Stock (BEAM) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of BEAM compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Beam Therapeutics Inc. Common Stock volatility is 3.74%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.48B | 1.10B | 1.46B | 1.34B | 1.47B | 451.68M | 8.58B | 8.64B | 7.49B |
| Equity Attributable To Parent (USD) | 1.24B | 733.55M | 981.33M | 733.47M | 826.74M | 245.56M | 5.07B | 4.61B | 4.10B |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 1.24B | 733.55M | 981.33M | 733.47M | 826.74M | 245.56M | 5.07B | 4.61B | 4.10B |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | 779.50M | 322.00M | 731.30M |
| Long-term Debt (USD) | - | - | - | - | - | - | 2.02B | 2.49B | 1.90B |
| Noncurrent Liabilities (USD) | 145.88M | 188.21M | 272.82M | 384.65M | 434.28M | 103.78M | 2.80B | 2.82B | 2.63B |
| Other Current Liabilities (USD) | 57.36M | 156.62M | 182.17M | 195.44M | 194.30M | 88.43M | 442.10M | 925.40M | 548.70M |
| Wages (USD) | 29.34M | 21.57M | 21.77M | 19.12M | 11.66M | 7.59M | 64.70M | 69.60M | 75.90M |
| Accounts Payable (USD) | 10.23M | 3.87M | 1.62M | 9.03M | 7.47M | 6.31M | 199.80M | 213.60M | 134.10M |
| Current Liabilities (USD) | 96.94M | 182.07M | 205.57M | 223.60M | 213.44M | 102.34M | 706.60M | 1.21B | 758.70M |
| Liabilities (USD) | 242.82M | 370.28M | 478.39M | 608.24M | 647.72M | 206.12M | 3.51B | 4.02B | 3.39B |
| Other Non-current Assets (USD) | 107.99M | 114.26M | 123.71M | 133.20M | 117.19M | 104.84M | 2.65B | 2.68B | 2.23B |
| Intangible Assets (USD) | - | - | - | - | - | - | 2.22B | 2.31B | 2.10B |
| Fixed Assets (USD) | 104.50M | 111.41M | 124.96M | 115.62M | 84.26M | 38.51M | 815.70M | 787.90M | 729.70M |
| Noncurrent Assets (USD) | 212.49M | 225.68M | 248.67M | 248.82M | 201.45M | 143.36M | 5.69B | 5.77B | 5.06B |
| Other Current Assets (USD) | 68.69M | 27.45M | 11.04M | - | 307.41M | 8.62M | 1.05B | 1.13B | 882.90M |
| Inventory (USD) | - | - | - | - | - | - | 1.84B | 1.74B | 1.55B |
| Cash (USD) | 1.20B | 850.70M | 1.20B | 1.10B | 965.60M | 299.70M | - | - | - |
| Current Assets (USD) | 1.27B | 878.15M | 1.21B | 1.09B | 1.27B | 308.32M | 2.89B | 2.86B | 2.43B |
| Assets (USD) | 1.48B | 1.10B | 1.46B | 1.34B | 1.47B | 451.68M | 8.58B | 8.64B | 7.49B |
News and Insights
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directorsneutral
Kyverna Therapeutics announced the appointments of Sravan K. Emany and Andrew Miller to its Board of Directors as the company advances toward commercialization of its cell therapies for autoimmune diseases. Emany, currently CFO of Beam Therapeutics, brings capital markets and rare disease expertise, while Miller, a Time Magazine honoree and former Karuna Therapeutics leader, adds clinical development and product approval experience. Dan Spiegelman has stepped down from the Board.
Beam Therapeutics announced a $500 million senior secured credit facility with Sixth Street, including $100 million funded at close and up to $400 million available through clinical, regulatory, and commercial milestones. The seven-year non-dilutive financing will support the anticipated commercial launch of ristoglogene autogetemcel (risto-cel) for sickle cell disease, with interest at approximately 10% annually and maturity in early 2033.
Beam Therapeutics announced it will present fourth quarter and full year 2025 financial results along with a new liver-targeted genetic disease program on February 24, 2026. The company also announced strategic priorities for its genetic disease and hematology franchises, with FDA alignment on an accelerated approval pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency.
Beam Therapeutics presented promising clinical trial results for risto-cel, a base editing cell therapy for sickle cell disease, showing high hemoglobin F induction, reduced hemoglobin S, and durable anemia resolution in 31 patients.
Several healthcare and AI-driven companies are demonstrating significant potential in transforming medical technologies, offering innovative therapies and solutions across various medical domains like gene editing, telehealth, and precision medicine.
Editas Medicine is a promising clinical-stage biotech company at the forefront of the gene-editing revolution with its unique in vivo CRISPR approach. However, the company faces significant technical challenges, a long road to commercialization, and weak fundamentals, making it a speculative investment.
Beam Therapeutics announced that the FDA has granted orphan drug designation to BEAM-302, a potential treatment for alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder affecting the lungs and liver. The designation provides benefits to support the development and evaluation of BEAM-302, which has shown promising initial safety and efficacy data in a Phase 1/2 trial.
Beam Therapeutics, a gene-editing company, reported Q1 earnings that missed analyst expectations, leading to a 19% drop in its stock price. The company's cash runway extends into 2028, which could give it time to develop its pipeline programs.
Beam Therapeutics, a biotechnology company, announced the pricing of a $500 million public offering of its common stock and pre-funded warrants. The company plans to use the proceeds to advance its base editing platform, research and development, and potential pivotal trials.